결장직장암 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global colorectal cancer therapeutic market size is expected to reach USD 35.48 Billion in 2034 from USD 17.23 Billion in 2025, growing at a CAGR of 8.36 during 2026-2034.This market is experiencing substantial growth driven by the increasing incidence of colorectal cancer and the rising emphasis on early diagnosis and treatment. Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, prompting healthcare systems to invest in advanced therapeutic solutions. Treatment options such as chemotherapy, targeted therapy, immunotherapy, and surgical interventions are continuously evolving to improve patient outcomes. The growing awareness of screening programs and early detection is also significantly contributing to market expansion across both developed and emerging regions.

Key drivers include advancements in oncology research, increasing healthcare expenditure, and the growing adoption of personalized medicine. Pharmaceutical companies are focusing on developing innovative therapies, including biologics and immune checkpoint inhibitors, to enhance treatment efficacy. The expansion of clinical trials and collaborations between research institutions and biotech firms are accelerating drug development. Additionally, supportive government initiatives and reimbursement policies are encouraging patients to seek timely treatment, further boosting market growth.

Future prospects for this market remain highly promising, with continuous innovation in targeted therapies and combination treatments. The integration of artificial intelligence and biomarker-based diagnostics will enable more precise and effective treatment planning. Emerging markets are expected to offer significant growth opportunities due to improving healthcare infrastructure and awareness. As research continues to advance, the colorectal cancer therapeutic market is poised for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Therapy

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Others

By Cancer Type

• Colorectal Adenocarcinoma
• Gastrointestinal Carcinoid Tumors
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

COMPANIES PROFILED

• Genentech Inc., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb, Sanofi, Merck Sharp & Dohme Corp., Taiho Pharmaceutical (Otsuka Pharmaceutical Co. Ltd.), Bayer AG, Regeneron Pharmaceuticals Inc., Novartis AG, Ipsen Biopharmaceuticals Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL COLORECTAL CANCER THERAPEUTIC MARKET: BY THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy
• 4.2. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COLORECTAL CANCER THERAPEUTIC MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Colorectal Adenocarcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Gastrointestinal Carcinoid Tumors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COLORECTAL CANCER THERAPEUTIC MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL COLORECTAL CANCER THERAPEUTIC MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy
  • 7.2.2 By Cancer Type
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy
  • 7.3.2 By Cancer Type
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy
  • 7.4.2 By Cancer Type
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy
  • 7.5.2 By Cancer Type
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy
  • 7.6.2 By Cancer Type
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL COLORECTAL CANCER THERAPEUTIC INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Genentech Inc
  • 9.2.2 Eli Lilly And Company
  • 9.2.3 Pfizer Inc
  • 9.2.4 Teva Pharmaceutical Industries Ltd
  • 9.2.5 Bristol Myers Squibb
  • 9.2.6 Sanofi
  • 9.2.7 Merck Sharp & Dohme Corp
  • 9.2.8 Taiho Pharmaceutical (Otsuka Pharmaceutical Co. Ltd.)
  • 9.2.9 Bayer AG
  • 9.2.10 Regeneron Pharmaceuticals Inc
  • 9.2.11 Novartis AG
  • 9.2.12 Ipsen Biopharmaceuticals Inc